Reinhold Wimberger-Friedl

This inventor holds 42 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 36 EPO patents, primarily in Digital Pathology. Top assignees: Koninklijke Philips Corporation N.v., Biocartis, Nv, Koninklike Philips N.v.. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Reinhold Wimberger-Friedl. Retrieved from https://idiyas.com/inventor/reinhold-wimberger-friedl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 42 (Patent Applications = 13)

% Patents Active = 71.4

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 36 (Patent Applications = 74)

Average Co-Inventor Count = 3.1

ph-index = 7

Forward Citations = 318(Granted Patents)

Location History:

AE Eindhoven, NL (2015)
Veldhoven, NL (2009 - 2019)
Eindhoven, NL (1998 - 2022)
Waalre, NL (2020 - 2024)

Company Filing History:

38 out of 21,919

Koninklijke Philips Corporation N.v.

Koninklike Philips N.v.

patents

4. 1 out of 14,087

U.S. Philips Corporation

patents

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Digital Pathology

Biosensing

Microfluidics

Cell Preservation

DNA Sequencing

Imaging

Risk Assessment

Sample Analysis

Microarray

Biological Samples

Radiology

Tissue Analysis

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12417848 - Prediction tool for patient immune response to a therapy (2025-09-16),

2. 12198346 - Combining pH and metabolic activity imaging for response assessment in immune therapy (2025-01-14),

3. 12191005 - Radiology-based risk assessment for biopsy-based scores (2025-01-07),

4. 12100137 - System for analysis of microscopic data using graphs (2024-09-24),

5. 12065633 - Cell preservation or culturing arrangement (2024-08-20),

6. 12014492 - Characterizing lesions in radiology images (2024-06-18),

7. 11538589 - Identifying adverse events (2022-12-27),

8. 11513038 - Sample holder for biological samples (2022-11-29),

9. 11389667 - Methods and apparatus for reducing risk to a subject undergoing radiotherapy-based treatment (2022-07-19),

10. 11199546 - Stratification of patients for assessing the suitability of a therapy (2021-12-14),

11. 11048911 - Apparatus for determining cellular composition information in one or more tissue samples (2021-06-29),

12. 11001056 - Printing control device to control printing of a cover layer on a sample (2021-05-11),

13. 10867443 - Information transformation in digital pathology (2020-12-15),

14. 10724078 - Spatial mapping of molecular profiles of biological tissue samples (2020-07-28),

15. 10685210 - Tissue microarray registration and analysis (2020-06-16),

Title: Reinhold Wimberger-Friedl: Innovator in Cancer Therapy Technologies

Introduction: Reinhold Wimberger-Friedl is a prominent inventor based in Eindhoven, Netherlands, recognized for his significant contributions to medical imaging technology with a focus on cancer therapy. With an impressive portfolio of 41 patents, Reinhold has dedicated his career to advancing methodologies that enhance the assessment of tumor responses to treatment.

Latest Patents: Among his latest patents are groundbreaking innovations that combine pH and metabolic activity imaging for cancer therapy response assessment. This computerized system is designed to monitor cancer therapy by receiving multiple input images that record metabolic activity and extracellular pH levels. The system's evaluator assesses changes over time in both metabolic activity and pH levels, providing crucial indications about the effectiveness of cancer therapies.

Another notable patent involves a computer-implemented method for determining tumor heterogeneity through radiological image analysis. This method calculates tumor activity values at different locations and assesses tumor heterogeneity by determining the proportion of the tumor with activity above a predetermined threshold, leading to accurate biopsy-based scores.

Career Highlights: Reinhold has worked with renowned companies such as Koninklijke Philips Corporation and Biocartis, where he played a critical role in developing innovative technologies that push the boundaries of medical research and treatment.

Collaborations: Throughout his career, Reinhold has collaborated with distinguished colleagues, including Anke Pierik and Pieter Jan Van Der Zaag. Their teamwork has facilitated advancements in the field and contributed to the successful launch of innovative healthcare solutions.

Conclusion: Reinhold Wimberger-Friedl exemplifies the spirit of innovation within the medical technology sector. His notable patents and collaborative efforts reflect his commitment to improving cancer therapy assessment. As he continues to innovate, his work remains vital for both healthcare professionals and patients seeking effective cancer treatment options.

Profile summary based on public USPTO records.